乙亚胺致急性白血病1例

乙亚胺作为一种抗代谢药 ,临床上常用于银屑病的治疗。但在治疗过程中我们发现 1例病人引起急性粒 单核细胞白血病 ,作者未见国内文献报道 ,现报告如下。病人 ,男性 ,46ａ,已婚 ,农民。因发热、乏力、进行性皮肤苍白 0 .5ｍｏ入院。该病人既往体健 ,2ａ前因患银屑病自服乙亚胺片 (ｅｔｈｙｌｅｎｅｄｉａｍｉｎｅｔｅｔｒａａｃｅｔｙｌｉｍｉｄｅ ,南京第二制药厂产 ,批号 2 0 0 0 0 3 0 3及 2 0 0 0 0 5 0 1,规格 :每片 10 0ｍｇ)每日3 0 0～ 60 0ｍｇ ,其中 ,连续服药每日 60 0ｍｇ时间达 2ｍｏ。用药后银屑病基本治愈 ,以后间断用药维…     

Severe neuroexcitatory symptoms after anaesthesia--with focus on propofol anaesthesia

Delayed neuroexcitatory symptoms after an uneventful anaesthesia are uncommon, although described in many reports. We want to report on two cases. The first patient developed muscle hypertonicity, jerky movements and unconsciousness after an uneventful anaesthesia with propofol, and later the same thing happened after anaesthesia with thiopentone. The second patient developed similar symptoms after an uneventful anaesthesia with propofol, but she never recovered completely after this and is now severely disabled. A search of the literature and the Swedish adverse drug reactions register revealed many similar cases. In both our patients the causal relationship between propofol and the neuroexcitatory symptoms remains uncertain, but we want to alert readers about this possible adverse reaction.     

Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma

ObjectiveTo investigate the effects of hand–foot syndrome (HFS) and fatigue on disease progression and survival in patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma.MethodsA retrospective analysis of patients with advanced hepatocellular carcinoma treated with sorafenib in our hospital from 1 October 2018 to 31 October 2021 was performed, and clinical and pathological data and follow-up results were obtained. Patients were divided into groups according to the severity of HFS and fatigue. Survival analysis among the groups was performed using the Kaplan–Meier method, continuous variables were analyzed using the t-test, and factors associated with survival were evaluated using multivariate Cox regression analysis.ResultsThe study included 150 men and 23 women with a mean age of 60.77 years (range: 40–85 years). The median overall survival (OS), progression-free survival (PFS), and time to tumor progression (TTP) increased with increasing severity of HFS. Conversely, the median OS, PFS, and TTP decreased with increasing severity of fatigueConclusionHFS and fatigue were independent risk factors affecting TTP, PFS, and OS among patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma.     

1例泰素帝外渗的护理

泰素帝(多西紫杉醇、多西他赛、紫杉特尔)是紫杉醇的半合成衍生物,主要成份是从紫杉的树干、树皮或针叶中提取或半合成的,其作用机理是在肿瘤细胞分裂时能与细胞微管蛋白结合,促进细胞中微管稳定和聚合,抑制微管解聚,使细胞有丝分裂受阻,从而抑制肿瘤生长[1]。临床多用于乳腺癌、非小细胞肺癌、卵巢癌等治疗。在应用泰素帝过程中,一旦发生外渗,如不及时处理,轻者会致局部组织红肿热痛,重者会引起周围组织坏死、溃烂、甚至功能障碍。2007年4月,我科有1例患者在静滴泰素帝时,意外发生了外渗,经及时给予处理,26天后患者康复出院,现报道如下。病…     

75%酒精按摩治疗小儿输液渗漏肿胀的效果观察

目的探讨75%酒精湿润按摩治疗小儿静脉输液局部渗漏肿胀的可行性。方法将67例输液肿胀患儿随机分为实验组和对照组,分别采用75%酒精湿润按摩和50%硫酸镁湿敷进行比较。结果实验组肿胀消退速度优于对照组(P<0.05)。结论75%酒精湿润按摩治疗输液渗漏肿胀,效果显著,经济、实用,患儿和家长易接受。     

Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review

BackgroundAccumulating data suggest antiviral effects of povidone-iodine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. This narrative review aims to examine the antiviral mechanisms of povidone-iodine, efficacy of povidone-iodine against the SARS-CoV-2 virus, and safety of povidone-iodine to human epithelial cells and thyroid function.MethodsWe searched the electronic databases PubMed, Embase, Cochrane Library, ClinicalTrials.gov and World Health Organization’s International Clinical Trials Registry Platform for articles containing the keywords “povidone-iodine”, “SARS-CoV-2” and “COVID-19” from database inception till 3 June 2021.ResultsDespite in vitro data supporting the anti-SARS-CoV-2 effects of povidone-iodine, findings from clinical studies revealed differences in treatment response depending on study settings (healthy vs. hospitalized individuals), treatment target (nasal vs. oral vs. pharynx), method of administration (oral rinse vs. gargle vs. throat spray) and choice of samples used to measure study endpoints (nasopharyngeal vs. saliva). One large-scale clinical trial demonstrated reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak. Povidone-iodine is also used to disinfect the oro-pharyngeal space prior to dental or otolaryngology procedures. Although existing data suggest minimal impact of povidone-iodine on thyroid function, high-quality safety data are presently lacking.ConclusionsPovidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings.

Key messages

• Accumulating data suggest antiviral effects of povidone-iodine against the SARS-CoV-2 virus.
• Findings from clinical studies reveal differences in treatment response depending on study settings, treatment target, method of administration and choice of samples used to measure study endpoints. One large-scale clinical trial observed reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak.
• Povidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings.

     

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance

Objective To evaluate the safety profile of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in clinical practice in Japan through an all-case post-marketing surveillance. Methods This was a nationwide non-interventional observational study conducted in Japan. The study included all patients who received ixazomib from May 24 to September 24, 2017. Ixazomib was administered to RRMM patients according to the Japanese package insert. All enrolled patients were observed until the completion of the sixth treatment cycle or until ixazomib discontinuation. The patient treatment course, including adverse events (AEs), was reported. Results The safety analysis set included 741 patients; the median age was 71 (range 35-92) years old, and the median number of prior treatment lines was 3 (range 1-30). Adverse drug reactions (ADRs) occurred in 572 (77.2%) patients, most commonly being thrombocytopenia (49.9%), diarrhea (29.2%), and nausea (12.4%). Serious ADRs occurred in 193 (26.0%) patients, most commonly being thrombocytopenia (9.9%) and diarrhea (5.9%). Thrombocytopenia, severe gastrointestinal disorders, infections, skin disorders, and peripheral neuropathy were prespecified as ADRs of clinical importance; the frequency of these ADRs (grade ≥3) were 28.5%, 9.4%, 7.4%, 2.2%, and 1.3%, respectively. Treatment discontinuation was most common with thrombocytopenia and severe gastrointestinal disorders (49 and 43 patients, respectively). Eleven patients died due to ADRs (16 events). Conclusion These results suggest that ixazomib has a tolerable safety profile in clinical practice in Japan. However, close AE management for thrombocytopenia and gastrointestinal disorders should be considered.     

中性粒细胞与高密度脂蛋白胆固醇比值对急性心肌梗死病人院内主要心血管不良事件的预测价值

目的探讨中性粒细胞与高密度脂蛋白胆固醇( HDL-C)的比值( NHR)对 AMI病人发生院内 MACE的预测价值以及 NHR与 Gensini评分量化的冠状动脉病变严重程度、左室射血分数( LVEF)量化的心脏泵功能的潜在关联。方法纳入 2018年 1月至 2022年 1月东南大学附属中大医院住院并接受冠状动脉造影的 546例 AMI病人。收集人口统计学数据、临床资料及计算 Gensini评分,依据住院期间是否发生 MACE,分为 MACE组( n=105)和非 MACE组( n=441)。使用受试者操作特征曲线(ROC曲线)检验 NHR预测院内 MACE的能力,并确定最佳截断值。使用多因素 logistic回归分析院内 MACE的影响因素,时,采用线性回归分析 NHR对 Gensini评分、 LVEF值的影响,并通过 Graphpad prism绘图进行可视化处理。院内 MACE定义同为:住院死亡、心源性休克、致血流动力学紊乱的恶性心律失常(包括室颤、持续性室速、高度及三度房室传导阻滞)等。结果MACE组的 NHR［13.64(9.89,18.19)］显著高于非 MACE组［7.73(5.83,10.07)］并且 NHR对 AMI病人院内 MACE具有较强的预测价值［AUC:0.84,95%CI:(0.79,0.88),P<0.001］调整混杂因素后,多因素二元,logistic回归分析显示 NHR是 AMI病人院内MACE的独立危险因素［OR:1.29,95%CI:(1.16,1.43),P<0.001］。线性回归分析显示 NHR与 AMI病人 Gensini评分呈显著正相关( P<0.001)与 LVEF呈显著负相关( P<0.001)。结论,本研究证实 NHR是 AMI病人院内 MACE的有力预测指标,是院内MACE的独立危险,因素之一,与 Gensini评分量化的冠状动脉病变严重程度呈显著正相关,与 LVEF量化的心脏泵功能呈显著负相关,可用于早期识别 AMI病人院内 MACE的高危人群,辅助临床诊疗。